Catalog No.
Product Name
Application
Product Information
Citations
-
NLRP3 Inhibitor
NLRP3-IN-27 is a selective inhibitor of the NLRP3 inflammasome, exhibiting an IC50 value of 0.55 μM. This compound is instrumental in investigating the role of NLRP3 in inflammatory processes and immune response modulation. It is a valuable tool for researchers studying the molecular mechanisms of inflammation and potential therapeutic strategies for associated diseases. -
NLRP3 Inflammasome Inhibitor
NLRP3-IN-86 is a selective inhibitor of the NLRP3 inflammasome. This compound demonstrates significant potency in reducing lipopolysaccharide (LPS) and Nigericin-induced lactate dehydrogenase release, with IC50 values of 2.69 μM in THP-1 cells and 1.75 μM in J774A.1 cells. Additionally, NLRP3-IN-86 effectively inhibits gasdermin D cleavage and interleukin-1 beta (IL-1β) secretion, thereby mitigating pyroptosis. This reagent is ideally suited for investigations into inflammatory processes and the underlying mechanisms of pyroptotic cell death. -
NLRP3 Inhibitor
NLRP3-IN-8 is a potent inhibitor of the NLRP3 inflammasome, acting through direct binding with an IC50 of 1.23 μM against IL-1β. This compound demonstrates notable metabolic stability, with a half-life of 138.63 minutes in liver microsomes, and exhibits minimal toxicity, as indicated by an IC50 greater than 100 μM against L02 cells. NLRP3-IN-8 is valuable for research into inflammatory disorders and potential therapeutic interventions targeting the NLRP3 pathway. -
NLRP3 Inhibitor
NLRP3-IN-31 is a selective inhibitor of the NLRP3 inflammasome, exhibiting an IC50 value in the range of 0.3-0.5 μM. This compound effectively modulates the activation of NLRP3, making it a valuable tool for studying inflammatory pathways. NLRP3-IN-31 can be utilized in research focused on autoinflammatory diseases, metabolic disorders, and neuroinflammation, aiding in the understanding of inflammasome-mediated processes. -
NLRP3 Inhibitor
NLRP3-IN-15 is a selective inhibitor of the NLRP3 inflammasome, targeting the pathway responsible for the activation of pro-inflammatory cytokines. With an IC50 of 0.114 μM, NLRP3-IN-15 effectively inhibits the release of IL-1β, a key mediator in inflammatory responses. This compound is suitable for investigating the role of NLRP3 in various inflammatory disorders and related research applications. -
NEK7 Degrader
NEK7 degrader-2 (Compound 25) is a targeted NEK7 degrader that facilitates dose-dependent degradation of NEK7 specifically in human PBMC-derived macrophages. This compound effectively reduces the release of pro-inflammatory cytokine IL-1β triggered by NLRP3 inflammasome activation. NEK7 degrader-2 serves as a valuable tool for investigating the mechanisms underlying inflammatory diseases. -
NLRP3 Inhibitor
NLRP3-IN-69 is a selective inhibitor of the NLRP3 inflammasome, targeting the activation of NF-κB p65. This compound effectively reduces LPS-induced overexpression of pro-inflammatory cytokines including IL-1β, as well as iNOS and COX-2, while inhibiting nitric oxide generation with an IC50 of 5.66 μM. NLRP3-IN-69 serves as a valuable tool in research focused on inflammatory diseases and the modulation of the immune response. -
NLRP3 Inhibitor
NLRP3-IN-62 is a selective inhibitor of the NLRP3 inflammasome, demonstrated to effectively inhibit pyroptosis in THP-1 cells with an IC50 of 0.7 nM. Additionally, it suppresses the release of interleukin-1 beta (IL-1β) with an IC50 of 108.5 nM. This compound serves as a valuable tool for research in inflammation and immune responses, particularly in studies related to diseases involving pyroptotic cell death. -
NLRP3 Modulator
NLRP3 Modulator 7 is a specific inhibitor of the NLRP3 inflammasome, effectively regulating its activity. This compound demonstrates potent inhibitory effects on interleukin-1 beta (IL-1β) secretion, with an IC50 value of less than 500 nM. NLRP3 Modulator 7 is applicable in research focused on inflammatory diseases and disorders related to the NLRP3 pathway. -
NLRP3 Inflammasome Inhibitor
NLRP3-IN-77 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an IC50 value of 5.36 nM in suppressing the viability of THP-1 cells. This compound effectively reduces the secretion of pro-inflammatory cytokines, specifically interleukin-1β (IL-1β) and interleukin-18 (IL-18). NLRP3-IN-77 is a valuable tool for investigating diseases associated with aberrant NLRP3 inflammasome activation, including various cancers and inflammatory disorders. -
Anti-inflammatory Agent
Macarangin is an anti-inflammatory agent isolated from propolis. It exhibits significant DPPH radical-scavenging activity and demonstrates anti-inflammatory effects by inhibiting the activation of the NLRP3 inflammasome. This compound is valuable for research applications focused on inflammation pathways and oxidative stress. -
NLRP3 Inhibitor
NLRP3-IN-22 is a selective inhibitor of the NLRP3 inflammasome, demonstrating an inhibition rate of 67% at a concentration of 10 μM. This compound is useful for studying the role of NLRP3 in inflammatory processes and can be applied in various research areas, including immunology and disease models related to chronic inflammation. Its selective inhibition makes it a valuable tool for elucidating the mechanisms underlying NLRP3-mediated pathologies. -
NLRP3 Inhibitor
Selnoflast monopotassium is a selective and reversible small molecule inhibitor targeting the NLRP3 inflammasome. It effectively inhibits IL-1β release induced by NLRP3 activation in monocyte-derived macrophages from individuals with Alzheimer's disease. This compound shows significant promise for research applications related to Alzheimer's disease and other systemic inflammatory disorders, including ulcerative colitis and chronic obstructive pulmonary disease. -
COX-2/NLRP3 Inhibitor
COX-2/NLRP3-IN-1 is a selective inhibitor targeting both COX-2 and the NLRP3 inflammasome, with an IC50 of 1.53 μM for COX-2. This compound exhibits notable anti-inflammatory properties by disrupting the NF-κB/NLRP3 signaling pathway, making it a valuable tool for research into inflammatory diseases. It is suitable for studying the roles of COX-2 and NLRP3 in various biological processes and therapeutic interventions. -
NLRP3 Inhibitor
NLRP3-IN-38 is a selective inhibitor of the NOD-like receptor protein 3 (NLRP3), known for its role in mediating inflammatory responses through inflammasome activation. With an EC50 value of 23 nM, it effectively reduces the activation of the NLRP3 inflammasome, making it a valuable tool for research into inflammatory diseases. This compound is suited for studies evaluating the modulation of NLRP3-related signaling pathways and the development of therapeutic strategies targeting NLRP3-mediated inflammation. -
NLRP3 Inhibitor
NLRP3-IN-82 is a potent inhibitor of the NLRP3 inflammasome, exhibiting an IC50 of less than 5 nM. This compound demonstrates significant biological activity in the modulation of inflammatory pathways and is applicable in research focused on neurological diseases such as Alzheimer's disease, inflammatory conditions like inflammatory bowel disease, and metabolic disorders including obesity. Its selective inhibition of NLRP3 makes it a valuable tool for studying the underlying mechanisms of these pathologies. -
NLRP3 Inhibitor
NLRP3-IN-14 is a selective inhibitor of the NLRP3 inflammasome, exhibiting a binding affinity (KD) of 5.87 μM. This compound effectively inhibits the release of interleukin-1 beta (IL-1β), with an IC50 value of 0.131 μM. NLRP3-IN-14 is valuable for research into inflammatory processes and the development of therapeutics targeting NLRP3-associated diseases. -
NLRP3 Inhibitor
NLRP3-IN-34 is a potent inhibitor of the NLRP3 inflammasome, targeting its activation and downstream signaling. It effectively inhibits reactive oxygen species (ROS) production and interleukin-1 beta (IL-1β) release, exhibiting an IC50 of 0.48 μM in J774A.1 cells. Additionally, NLRP3-IN-34 has demonstrated the capability to inhibit pyroptosis and exhibits anti-inflammatory effects, particularly in models of dextran sulfate sodium (DSS)-induced peritonitis. This compound is valuable for research focused on inflammation and related disease mechanisms. -
NLRP3 Inhibitor
NLRP3-IN-26 is a specific inhibitor of the NLRP3 inflammasome, demonstrating an IC50 of 0.13 μM. This compound is useful for studying the role of NLRP3 in inflammatory processes and can be applied in models of DSS-induced colitis to elucidate its impact on intestinal inflammation and immune responses. -
NLRP3 Inhibitor
NLRP3-IN-71 is a selective inhibitor of the NLRP3 inflammasome, demonstrating the ability to inhibit IL-1β secretion. This compound is characterized by its blood-brain barrier permeability and oral bioavailability, making it a valuable tool in the study of neurodegenerative diseases and related inflammatory mechanisms. It offers researchers a practical means to investigate the role of NLRP3 in various neurological disorders. -
NLRP3 Inhibitor
JNJ-79883960 is a potent NLRP3 inhibitor, designed to modulate the NLRP3 inflammasome's activity. This compound has demonstrated efficacy in reducing inflammation, making it a valuable tool for investigating inflammatory pathways and associated diseases. Its application includes research into conditions such as autoimmune disorders and chronic inflammatory diseases, providing insights into potential therapeutic interventions. -
NLRP3 Inhibitor
NLRP3-IN-65 is a selective inhibitor of the NLRP3 inflammasome, a key component of the innate immune response. This compound exerts significant biological activity by inhibiting the activation of NLRP3, thereby modulating inflammatory responses. It is valuable for research applications related to autoinflammatory diseases, chronic inflammation, and potential therapeutic strategies aimed at controlling NLRP3-mediated pathways. -
NOD-like Receptor (NLR) Inhibitor
NLRP3-IN-4 is a potent inhibitor of the NOD-like receptor (NLR) NLRP3 inflammasome, exhibiting oral bioavailability. This compound is characterized by its ability to mitigate inflammatory processes, making it particularly relevant for research in inflammatory diseases such as colitis. It is a valuable tool for investigating the role of NLRP3 in immune responses and inflammation modulation. -
NLRP3 Inhibitor
NLRP3-IN-64 is a selective inhibitor of the NLRP3 inflammasome, exhibiting an EC50 of 5 nM for the inhibition of NLRP3 activation. This compound is useful for investigating the role of NLRP3 in inflammatory diseases and provides a valuable tool for research in immune response modulation. Its application extends to studying the mechanisms underlying autoinflammatory conditions and potential therapeutic interventions. -
NQO2 Activator
NQO2 activator-1 is a selective activator of NAD(P)H:quinone oxidoreductase 2 (NQO2) that enhances enzymatic activity by 20.89% at a concentration of 10 μM. This compound exhibits a strong inhibitory effect on NLRP3 inflammasome activation, making it a valuable tool for studying inflammation and immunological responses. Research applications include investigations into conditions such as rheumatoid arthritis and other inflammatory disorders. -
NLRP3 Inhibitor
Sebrinoflast is a potent NLRP3 inhibitor, exhibiting an IC50 of ≤1 μM for human NLRP3. This compound is valuable in the study of inflammatory conditions and cardiovascular diseases such as non-alcoholic steatohepatitis (NASH) and atherosclerosis. Additionally, it serves as an important tool in neurological disease research, particularly for Alzheimer's disease. -
NLRX1 Modulator
(6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosahexaenoyl-CoA is a modulator of NLRX1, a member of the NLR family involved in the regulation of immune responses. This compound plays a significant role in the study of immune and metabolic disorders, offering insights into potential therapeutic mechanisms. Its unique structure facilitates research into cellular processes related to inflammation and metabolism. -
NLRP3 Inflammasome Inhibitor
NT-0527 is a selective inhibitor of the NLRP3 inflammasome, demonstrating oral bioavailability and effective permeability across the blood-brain barrier. This compound specifically prevents NLRP3 inflammasome formation, leading to decreased maturation and secretion of interleukin-1 beta (IL-1β). NT-0527 exhibits notable anti-inflammatory effects in models of acute inflammation, including the LPS/ATP-induced peritonitis model. It is a valuable tool for research into neuroinflammatory conditions, such as Parkinson's disease and Alzheimer's disease, as well as peripheral inflammatory disorders like type II diabetes and atherosclerosis involving the NLRP3 pathway. -
NOD-like Receptor (NLR) Inhibitor
GSK223 is a quinazolinone compound that acts as a selective inhibitor of the NOD1 pathway. It demonstrates potential anti-inflammatory activity by selectively inhibiting IL-8 release in response to iE-DAP stimulation, while leaving IL-8 secretion unaffected from TNF receptor, TLR2, or NOD2 agonists. Additionally, GSK223 does not directly inhibit RIP2 kinase activity, making it a valuable tool for studying NOD-like receptor signaling and its implications in inflammatory responses. -
NOD-like Receptor (NLR) Inhibitor
NLRP3-IN-53 is a potent inhibitor of the NOD-like receptor NLRP3, exhibiting an IC50 of 3.4 nM. This compound is utilized in research to investigate the roles of the NLRP3 inflammasome in various inflammatory diseases and immune responses. Its selective inhibition helps elucidate the mechanistic pathways involved in NLRP3-related signaling, making it a valuable tool for studying therapeutic targets in the context of autoimmunity and metabolic disorders. -
NLRP3 Inhibitor
NLRP3-IN-58 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an IC50 value of 3.85 μM. At a concentration of 10 μM, it effectively reduces IL-1β release by 33%. This compound is valuable for research applications focused on inflammatory pathways and the modulation of innate immune responses. -
NLRP3 Inhibitor
NLRP3-IN-56 is a potent inhibitor of the NLRP3 inflammasome, effectively suppressing IL-1β secretion in THP-1 cells with an IC50 of 9.7 nM. This compound serves as a valuable tool for investigating NLRP3-mediated inflammatory responses and associated pathologies. Its ability to modulate IL-1β levels makes it suitable for research into diseases characterized by NLRP3 activation. -
NLRP3 Inhibitor
NLRP3-IN-28 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an EC50 of 0.07 μM in the inhibition of Nigericin-induced pyroptosis. This compound effectively reduces inflammatory responses in vivo, making it a valuable tool for investigating NLRP3-related diseases and inflammatory pathways. Its application in research provides insights into therapeutic strategies targeting inflammasome activation and related inflammatory conditions. -
Inflammasome Inhibitor
3-Et-3TC is a potent inhibitor of the NLRP3 inflammasome, demonstrating its capacity to modulate inflammasome activation. This compound is valuable for investigating the underlying mechanisms of retinal degenerative diseases and other inflammatory conditions. Its structural modification from Lamivudine enhances its efficacy in biochemical research applications targeting inflammasome pathways. -
Gingerol
Diacetoxy-6-gingerdiol is a derivative of gingerol that exhibits anti-inflammatory and antioxidant properties. This compound has been shown to protect the extracellular matrix of nucleus pulposus cells and reduce intervertebral disc degeneration through the inhibition of the IL-1β-mediated NLRP3 pathway. Its research applications include investigating mechanisms of inflammation and extracellular matrix preservation in musculoskeletal disorders. -
Stable Isotope
Carvedilol-d4 is a deuterated derivative of Carvedilol, a non-selective β/α-1 adrenergic receptor antagonist. It exhibits dose-dependent inhibition of lipid peroxidation with an IC50 value of 5 μM. Carvedilol acts as a multifaceted antihypertensive agent, demonstrating potential therapeutic applications in managing conditions such as angina and congestive heart failure. Additionally, it has been identified as an autophagy inducer and a modulator of the NLRP3 inflammasome, making it a valuable tool for research into cardiovascular and inflammatory diseases. -
Stable Isotope
Carvedilol-d3 is a deuterium-labeled analogue of Carvedilol, functioning primarily as a non-selective β/α-1 adrenergic receptor blocker. It exhibits significant biological activity by inhibiting lipid peroxidation in a dose-dependent manner with an IC50 value of 5 μM. This compound serves as a versatile antihypertensive agent and has potential applications in the treatment of angina and congestive heart failure. Furthermore, Carvedilol-d3 promotes autophagy and is known to inhibit the NLRP3 inflammasome, making it valuable for research involving inflammatory processes. -
Stable Isotope
Carvedilol-d5 is a deuterium-labeled analogue of Carvedilol, a non-selective β/α-1 adrenergic receptor blocker. It exhibits lipid peroxidation inhibition with an IC50 of 5 μM and serves as a versatile antihypertensive agent, showing potential in the treatment of angina and congestive heart failure. Additionally, Carvedilol functions as an autophagy inducer and inhibits the NLRP3 inflammasome, making it relevant for research in inflammatory pathways and cardiovascular health. -
Antioxidant
Dihydrolipoic Acid (DHLA) is a potent antioxidant primarily targeting reactive oxygen species. It demonstrates significant anti-inflammatory effects across various disease models. Research indicates that DHLA can modulate the ERK/Nrf2/HO-1/ROS/NLRP3 signaling pathway, effectively mitigating sickness behavior in LPS-induced rat models. This compound is valuable for studies related to depression and oxidative stress-related disorders. -
Dye/P2×7R Antagonist
Brilliant Blue G-250 is a dye that functions as a P2×7 receptor (P2×7R) antagonist. It exhibits selective inhibition of P2×7R, leading to the inactivation of the NLRP3 inflammasome, which is crucial in inflammatory processes. This compound is widely utilized for protein visualization in SDS-PAGE, providing a straightforward staining method alongside high quantitation capabilities in the Bradford protein assay, where protein concentrations are assessed by measuring absorbance at 595 nm. -
Antibiotic Agent
Cloxacillin sodium is a β-lactam antibiotic and a potent β-lactamase inhibitor with an IC50 of 0.04 µM. It exhibits significant antibacterial activity, particularly against Staphylococcus aureus, and can effectively attenuate the S. aureus-induced inflammatory response by inhibiting the activation of MAPK, NF-κB, and NLRP3-related proteins. This compound is relevant for research in antimicrobial resistance and inflammation pathways. -
Antibacterial Agent
Cloxacillin is an orally active antibacterial agent and β-lactamase inhibitor, exhibiting an IC50 of 0.04 µM. It effectively suppresses the inflammatory response induced by Staphylococcus aureus by inhibiting the activation of mitogen-activated protein kinases (MAPKs), nuclear factor kappa B (NF-κB), and proteins associated with the NLRP3 inflammasome. This compound is useful for research applications focused on bacterial infections and inflammatory processes. -
Pyroptosis Inducer
PenCB (PCB 118) is a potent pyroptosis inducer that primarily activates the NFκB-dependent NLRP3 inflammasome pathway. Its mechanism involves the induction of oxidative stress, which is mediated through the activation of the aryl hydrocarbon receptor (AhR) and subsequent upregulation of cytochrome P450 1A1. This compound is useful for studies examining inflammatory processes and cell death mechanisms, particularly in the context of pyroptosis-related research. -
Pyroptosis Inhibitor
Azalamellarin N is a selective inhibitor of pyroptosis, effectively modulating the inflammatory response by targeting upstream signaling pathways involved in NLRP3 inflammasome activation. This compound exhibits differential inhibitory effects on various pyroptosis inducers, with notable potency against Nigericin and R837. Its mechanism provides a valuable tool for investigating the role of pyroptosis in cellular processes and disease states, making it significant for research in inflammation and immune responses. -
NLRP3 Inhibitor
NLRP3-IN-78 is a potent inhibitor of the NLRP3 inflammasome, demonstrating a 46.72% inhibition rate in GSDMD-induced pyroptosis at a concentration of 5 μM. This compound effectively binds to the NLRP3 protein, hindering GSDMD-NT oligomerization and cleavage while also suppressing upstream NF-κB signaling. NLRP3-IN-78 serves as a valuable tool for investigating anti-inflammatory mechanisms and the role of NLRP3 in various disease models. -
Drd2 Agonist
UNC9995 is a β-arrestin2-biased agonist of the dopamine receptor Drd2. This compound inhibits NLRP3 inflammasome activation by promoting the interaction between β-arrestin2 and NLRP3, thereby preventing neuronal degeneration. Furthermore, UNC9995 activates Drd2/β-arrestin2 signaling, which mitigates the transcription of inflammation-related genes induced by the JAK/STAT3 pathway. Research shows that UNC9995 enhances depressive behavior in mouse models and improves astrocyte dysfunctions, making it a valuable tool for studying neuroinflammatory processes and mood disorders. -
NEK7 Molecular Glue Degrader
NEK7 degrader-3 is an orally active NEK7 molecular glue degrader with a DC50 of 33.1 nM, which effectively mediates the interaction between NEK7 and the E3 ligase cereblon, leading to the proteasomal degradation of NEK7. This degradation process attenuates NLRP3 inflammasome-mediated inflammatory responses, resulting in the inhibition of caspase-1 activity and the release of pro-inflammatory cytokines IL-1β, IL-1α, and IL-18. NEK7 degrader-3 demonstrates significant anti-inflammatory effects in LPS-induced neuroinflammation mouse models, serving as a valuable tool for research focused on neuroinflammation. -
Anti-inflammatory Agent
MBL-1 is an orally active anti-inflammatory agent that targets the hCOX-2 protein, demonstrating an IC50 of 5.77 μM. This compound effectively reduces the production of key pro-inflammatory mediators, including nitrogen oxide (NO), reactive oxygen species (ROS), IL-1β, and IL-18, by inhibiting the MAPK/NF-κB and NLRP3 signaling pathways. MBL-1 has shown protective effects against dextran sulfate sodium (DSS)-induced colitis, making it a valuable tool for research into ulcerative colitis and related inflammatory conditions. -
IDE/NLRP3 Inhibitor
ML345 is a selective inhibitor of insulin-degrading enzyme (IDE) and NLRP3, exhibiting an IC50 of 188 nM for IDE. By targeting the Cys819 residue, ML345 effectively inhibits IDE activity, while it binds non-covalently to NLRP3, modulating its function. This compound is known to inhibit the release of inflammatory cytokines such as IL-1β and IL-6, demonstrating significant anti-inflammatory properties. Additionally, ML345 has been shown to provide protective effects against miscarriage, making it a valuable tool for research in inflammation and reproductive health. -
Fas receptor Antagonist
Xelafaslatide is a Fas receptor antagonist that effectively inhibits Fas receptor signaling, thereby blocking downstream apoptosis and inflammatory pathways. This compound demonstrates significant potential in suppressing neuroinflammation and microglial activation in glaucoma models, offering protection to retinal ganglion cells and preventing axonal degeneration. Xelafaslatide is relevant for research focused on glaucoma and related neurodegenerative conditions.
